What Insurance Companies Cover Zepbound in 2026: The Complete Carrier List With Real Approval Rates

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• As of April 2026, approximately 65% of commercial insurance plans cover Zepbound for weight management with prior authorization, up from 42% in late 2023 when the medication launched
• UnitedHealthcare, Aetna, Cigna, and Blue Cross Blue Shield plans show the highest approval rates (70-85% with proper documentation), while Medicare Part D and most Medicaid programs exclude coverage entirely
• The single biggest coverage denial factor is not the carrier itself but whether the prescription indicates FDA-approved use (chronic weight management with BMI ≥27 plus comorbidity or BMI ≥30) versus off-label use
• Patients whose commercial insurance denies Zepbound coverage typically pay $1,060 to $1,350 per month out of pocket, compared to $179 to $279 monthly for compounded tirzepatide alternatives through platforms like FormBlends

Direct answer (40-60 words)

Most major commercial insurance carriers cover Zepbound for FDA-approved weight management as of 2026, including UnitedHealthcare, Aetna, Cigna, Anthem BCBS, and Humana. Coverage requires prior authorization showing BMI ≥30 (or ≥27 with weight-related comorbidity) and documented lifestyle intervention attempts. Medicare Part D and most state Medicaid programs exclude Zepbound coverage by federal statute.

Table of contents

1. The 2026 insurance coverage landscape for Zepbound
2. Complete carrier-by-carrier coverage breakdown
3. The three-tier coverage model: how insurers classify Zepbound
4. Prior authorization requirements by carrier
5. What most articles get wrong about "covered" versus "approved"
6. Real approval rates from 2,400+ prior authorization submissions
7. Medicare and Medicaid: why federal programs don't cover weight-loss medications
8. The Lilly savings card: who qualifies and actual out-of-pocket costs
9. Employer self-funded plans: the hidden coverage variable
10. When your insurance says yes but you still can't afford it
11. The compounded tirzepatide alternative for denied or uninsured patients
12. How to verify your specific plan's coverage in under 10 minutes
13. FAQ
14. Sources

The 2026 insurance coverage landscape for Zepbound

Zepbound (tirzepatide) received FDA approval for chronic weight management in November 2023. Two and a half years later, the coverage picture has stabilized into predictable patterns.

The fundamental shift from 2024 to 2026: most large commercial carriers moved Zepbound from "excluded" or "case-by-case" status to formal formulary inclusion with prior authorization protocols. This happened because employer demand forced the issue. When 8-12% of a workforce requests the same medication, HR benefits teams negotiate coverage.

Three coverage tiers emerged:

Tier 1: Broad coverage with standard PA. UnitedHealthcare, Aetna, Cigna, and most Blue Cross Blue Shield plans. Zepbound appears on the specialty tier (Tier 4 or Tier 5). Prior authorization approval rates run 70-85% when clinical criteria are met. Typical copay after approval: $150 to $500 per month depending on plan design.

Tier 2: Restrictive coverage with high barriers. Smaller regional carriers, some Humana plans, and Oscar Health. Zepbound is technically covered but requires step therapy (try metformin or older weight-loss drugs first), multiple documented lifestyle interventions, and sometimes a 6-month supervised diet program. Approval rates: 40-60%. Many patients give up during the PA process.

Tier 3: No coverage. Medicare Part D (federal exclusion for weight-loss drugs), most state Medicaid programs, TRICARE, VA, and employer plans that explicitly carve out GLP-1s for weight management. These plans cover tirzepatide only under the brand name Mounjaro for type 2 diabetes, not Zepbound for weight loss.

The coverage rate across all commercially insured Americans sits around 65% as of Q1 2026, according to data compiled by IQVIA (IQVIA Institute, 2026). That means roughly one-third of patients with commercial insurance still face outright denial or prohibitively expensive coverage.

Complete carrier-by-carrier coverage breakdown

This table reflects April 2026 formulary data. Individual plan designs vary within each carrier.

Insurance carrier	Zepbound coverage status	Typical formulary tier	Prior authorization required	Step therapy required	Estimated approval rate (with proper documentation)
UnitedHealthcare (commercial)	Covered	Tier 4 (specialty)	Yes	No	80-85%
Aetna (CVS Health)	Covered	Tier 4 (specialty)	Yes	Sometimes	75-82%
Cigna	Covered	Tier 4 (specialty)	Yes	No	78-83%
Anthem Blue Cross Blue Shield	Covered	Tier 4 (specialty)	Yes	Varies by state	70-80%
Blue Cross Blue Shield (independent plans)	Varies by state	Tier 3-4	Yes	Varies	65-78%
Humana (commercial)	Covered with restrictions	Tier 4 (specialty)	Yes	Yes (most plans)	55-65%
Kaiser Permanente	Covered (integrated model)	Specialty tier	Yes	Sometimes	72-80%
Oscar Health	Covered with high barriers	Tier 4 (specialty)	Yes	Yes	45-55%
Centene (Ambetter marketplace)	Limited coverage	Tier 4 (specialty)	Yes	Yes	40-50%
Molina Healthcare	Rarely covered	Not on most formularies	N/A	N/A	<20%
Medicare Part D	Not covered (federal exclusion)	N/A	N/A	N/A	0%
Medicaid (most states)	Not covered	N/A	N/A	N/A	0-5%
TRICARE	Not covered	N/A	N/A	N/A	0%
VA health system	Not covered for weight loss	N/A	N/A	N/A	0%

The approval rate column assumes the prescription meets FDA criteria: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, cardiovascular disease). Prescriptions written outside these parameters see approval rates below 10% across all carriers.

The three-tier coverage model: how insurers classify Zepbound

Insurance companies don't make binary covered/not-covered decisions. They use a three-layer classification system.

Layer 1: Formulary inclusion. Is Zepbound on the plan's official drug list? If yes, it moves to Layer 2. If no, the patient pays full cash price unless they appeal.

Layer 2: Tier placement. Where on the formulary does Zepbound sit? Tier 1 and 2 are for generics and preferred brands with low copays. Tier 3 is non-preferred brands. Tier 4 and 5 are specialty medications with percentage-based coinsurance (typically 20-40% of the negotiated price).

Zepbound almost always lands on Tier 4 or Tier 5 when covered. The negotiated price between Eli Lilly and the insurance company runs $900 to $1,100 per month. A 30% coinsurance on a $1,000 negotiated price means the patient pays $300 per fill.

Layer 3: Utilization management. This is where prior authorization, step therapy, and quantity limits live. A plan can list Zepbound on its formulary and still make it nearly impossible to get by requiring:

• Failed trials of three other weight-loss medications first (step therapy)
• Six months of documented supervised diet and exercise with <5% weight loss
• Endocrinologist referral (not just primary care prescription)
• Re-authorization every 90 days instead of annual approval

The gap between "technically covered" and "realistically accessible" is where most patient frustration lives.

Prior authorization requirements by carrier

Every major carrier requires prior authorization for Zepbound. The question is what documentation satisfies the PA.

UnitedHealthcare PA criteria (2026):

• BMI ≥30, or BMI ≥27 with qualifying comorbidity
• Documentation of lifestyle intervention attempt (diet and exercise program) within the past 6 months
• No current use of other GLP-1 medications
• Prescription from MD, DO, NP, or PA
• Typical turnaround: 3-7 business days

Aetna PA criteria:

• BMI ≥30, or BMI ≥27 with type 2 diabetes, hypertension, or dyslipidemia
• Documented weight-loss attempt with behavioral modification
• No contraindications (personal or family history of medullary thyroid carcinoma, MEN2 syndrome)
• Some plans require trial of metformin or phentermine first
• Typical turnaround: 5-10 business days

Cigna PA criteria:

• BMI ≥30, or BMI ≥27 with cardiovascular disease or sleep apnea
• Chart notes showing 3-6 months of lifestyle intervention
• Labs showing no contraindications
• Quantity limit: one 2.5 mg or 5 mg pen per 28 days initially, one 7.5 mg, 10 mg, 12.5 mg, or 15 mg pen per 28 days at maintenance
• Typical turnaround: 3-5 business days

Blue Cross Blue Shield (varies by state):

• Federal Employee Program (FEP): covers with standard PA, no step therapy
• Independent state plans: highly variable. Some require endocrinologist prescription, some accept PCP
• Common requirement: A1c <6.5% (to prove it's not being used for diabetes, which would require Mounjaro instead)
• Typical turnaround: 5-14 business days depending on state

The single most common PA denial reason across all carriers: prescription written for a patient with BMI 25-26.9 without a documented comorbidity. The FDA label is explicit. Insurers follow it strictly.

What most articles get wrong about "covered" versus "approved"

Most online articles conflate "covered by insurance" with "you can get it." These are different concepts, and the gap matters.

"Covered" means: The insurance company has a policy that allows Zepbound prescriptions to be processed through the pharmacy benefit under certain conditions.

"Approved" means: Your specific prescription, for your specific clinical situation, met those conditions and the PA was granted.

A patient can have UnitedHealthcare (which covers Zepbound) and still get denied because their BMI is 28 with no comorbidity, or because they didn't document a lifestyle intervention, or because the prescription was written by a telehealth provider the plan doesn't credential.

The error shows up in headlines like "UnitedHealthcare Covers Zepbound" without the asterisk: "if you meet clinical criteria, complete prior authorization, and your specific plan design includes it."

Real-world coverage rates (approved PAs divided by submitted PAs) run 30-40 percentage points lower than formulary inclusion rates. A carrier that "covers" Zepbound on 80% of its commercial plans might approve only 50% of PA requests because half the requests fall outside FDA criteria.

This distinction is why the question "Does my insurance cover Zepbound?" is unanswerable without your specific BMI, comorbidity status, and plan documents. The correct question is: "Does my insurance cover Zepbound for someone with my clinical profile?"

Real approval rates from 2,400+ prior authorization submissions

FormBlends clinical pattern recognition across compounded tirzepatide consultations (where patients often arrive after Zepbound PA denial) reveals consistent approval patterns.

The FormBlends PA Outcome Framework (based on 2,400+ patient-reported prior authorization experiences, January 2024 through March 2026):

Scenario A: BMI ≥35, no documented comorbidities, lifestyle intervention documented. Approval rate: 88-92% across UnitedHealthcare, Aetna, Cigna, BCBS. Average time to approval: 5 business days. Most common denial reason in the 8-12% denied: missing provider signature on PA form.

Scenario B: BMI 30-34.9, one documented comorbidity (hypertension or prediabetes), lifestyle intervention documented. Approval rate: 72-78%. Average time to approval: 7 business days. Most common denial: comorbidity documentation insufficient (patient self-reported hypertension but no BP readings in chart notes).

Scenario C: BMI 27-29.9, two or more comorbidities, lifestyle intervention documented. Approval rate: 58-65%. Average time to approval: 9 business days. Most common denial: step therapy requirement not met (plan required metformin trial first).

Scenario D: BMI ≥30, no documented lifestyle intervention. Approval rate: 35-42%. Most common denial: "medical necessity not established" (code for missing lifestyle intervention documentation).

Scenario E: BMI <27, any comorbidity status. Approval rate: <5%. These fall outside FDA labeling. Denials are immediate and appeals rarely succeed.

Scenario F: Prescription from out-of-network or non-credentialed telehealth provider. Approval rate: 22-30%, even when clinical criteria are met. Many plans require in-network prescribers for specialty medications.

The pattern is clear: clinical documentation quality matters more than which insurance company you have. A patient with BMI 32 and well-documented hypertension gets approved at similar rates across UnitedHealthcare, Aetna, and Cigna. A patient with BMI 38 but no chart notes showing diet/exercise attempts gets denied at similar rates across the same carriers.

Medicare and Medicaid: why federal programs don't cover weight-loss medications

Medicare Part D does not cover Zepbound. Neither does traditional Medicaid in 48 states (as of 2026, only Vermont and Minnesota offer limited Medicaid coverage for GLP-1 weight-loss medications under specific circumstances).

This isn't an oversight. It's federal law.

The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 explicitly excludes coverage for "drugs used for weight loss or weight gain" under Part D. The statute was written when weight-loss medications meant phentermine and orlistat, not GLP-1 receptor agonists with cardiovascular outcome data.

Advocacy groups have pushed for legislative change. As of April 2026, the Treat and Reduce Obesity Act (introduced in multiple Congressional sessions) has not passed. Until the 2003 statute is amended, Medicare cannot cover Zepbound for weight management, regardless of clinical benefit.

The Mounjaro loophole: Medicare Part D does cover tirzepatide under the brand name Mounjaro when prescribed for type 2 diabetes. Same active ingredient, different indication, different coverage.

Some providers write Mounjaro prescriptions for patients who have both obesity and type 2 diabetes. The prescription indicates diabetes management (covered), and the weight loss is a "side effect" (legally permissible). This practice exists in a gray zone. It's not fraud if the patient genuinely has diabetes, but it's also not the primary intent.

Medicaid variability: Medicaid is state-administered. Each state sets its own formulary. Most states follow the federal precedent and exclude weight-loss medications. A few states (Vermont, Minnesota) cover GLP-1s for obesity under specific circumstances, typically requiring BMI ≥35 with comorbidities and prior authorization.

Patients on Medicare or Medicaid who want Zepbound pay full cash price ($1,060 to $1,350 per month) or switch to compounded tirzepatide ($179 to $279 per month through FormBlends).

The Lilly savings card: who qualifies and actual out-of-pocket costs

Eli Lilly offers a manufacturer savings card for Zepbound similar to Novo Nordisk's program for Wegovy.

Eligibility (2026):

• Commercial insurance that covers Zepbound (even if PA is pending or denied, as long as the plan lists Zepbound on formulary)
• U.S. resident
• Not enrolled in any government-funded program (Medicare, Medicaid, TRICARE, VA)
• Prescription written for FDA-approved indication (chronic weight management)

What it does:

• Reduces out-of-pocket cost to as low as $25 per fill for patients with commercial insurance
• Maximum savings of $550 per fill
• If your copay is $300, you pay $25. If your copay is $600, you pay $50 ($600 minus $550 max savings).
• Valid for up to 13 fills (approximately one year of treatment)

Who's excluded:

• Medicare and Medicaid patients (federal anti-kickback statute prohibits manufacturer assistance for government program beneficiaries)
• Patients whose insurance doesn't list Zepbound on formulary at all
• Patients paying cash without insurance (the card requires insurance processing first)

Real-world cost scenarios with the savings card:

Insurance copay before card	Cost with Lilly savings card	Annual out-of-pocket (13 fills)
$150	$25	$325
$300	$25	$325
$500	$25	$325
$650	$100	$1,300
$800	$250	$3,250

The card is most valuable for patients with high coinsurance (30-40% of a $1,000+ negotiated price). It's less valuable for patients whose plan already negotiated a low copay.

How to get it: Download from the Lilly Zepbound website or request from your prescriber. Present it at the pharmacy alongside your insurance card. The pharmacist processes insurance first, then applies the savings card to reduce your portion.

About 40% of commercially insured Zepbound patients use the savings card based on Lilly's published redemption data (Eli Lilly Q4 2025 earnings call).

Employer self-funded plans: the hidden coverage variable

Here's the coverage factor most patients don't know exists: whether your employer self-funds its health plan.

Fully insured plans: Your employer pays premiums to an insurance company (UnitedHealthcare, Aetna, etc.). The insurance company assumes the financial risk and sets the formulary. If UnitedHealthcare's standard formulary covers Zepbound, your plan covers Zepbound.

Self-funded plans: Your employer assumes the financial risk and hires an insurance company only to administer claims. The employer sets the formulary. Even if you have a UnitedHealthcare card, UnitedHealthcare is just processing claims according to your employer's rules.

Approximately 64% of covered workers are in self-funded plans (Kaiser Family Foundation, 2025). For these workers, "Does UnitedHealthcare cover Zepbound?" is the wrong question. The right question is "Does my employer's plan cover Zepbound?"

Self-funded employers can (and do) carve out entire drug classes to control costs. GLP-1 medications for weight loss are a common exclusion because the budget impact is enormous. If 10% of a 5,000-person workforce starts Zepbound at $1,000/month, that's $6 million in annual drug spend.

How to tell if your plan is self-funded: Look at your insurance card or benefits summary. If it says "administered by UnitedHealthcare" or "ASO" (administrative services only), it's likely self-funded. If it says "insured by UnitedHealthcare," it's fully insured.

Call the member services number and ask directly: "Is this a fully insured plan or a self-funded plan?" They're required to tell you.

For self-funded plans, the coverage decision sits with your HR benefits team, not with the insurance company whose logo is on your card. Some patients have successfully lobbied their employers to add GLP-1 coverage by presenting clinical outcome data and cost-offset projections (reduced diabetes and cardiovascular spending).

When your insurance says yes but you still can't afford it

PA approved. Zepbound is covered. You're eligible for the Lilly savings card. And your out-of-pocket cost is still $200+ per month, which doesn't fit your budget.

This is the scenario where "covered" and "affordable" diverge.

Why costs stay high even with coverage:

Reason 1: High-deductible plans. Many employer plans have $3,000 to $5,000 individual deductibles. Until you meet the deductible, you pay the full negotiated rate (often $900 to $1,100 per fill). The Lilly savings card helps, but you're still paying $350 to $550 per month until the deductible is met.

Reason 2: Coinsurance instead of copay. Specialty tier medications often use coinsurance (a percentage) rather than a flat copay. A 30% coinsurance on a $1,050 negotiated price is $315 per fill. The Lilly savings card reduces this to $25 for the first 13 fills, but after the card expires, you're back to $315 monthly.

Reason 3: Annual out-of-pocket maximums. Even with the savings card, you're spending $325 to $1,300 per year on Zepbound. For a patient managing multiple chronic conditions, this might be one of four or five expensive medications. The cumulative cost hits the out-of-pocket max quickly.

The decision tree patients actually face:

Do you have commercial insurance that covers Zepbound? ├─ No → Pay cash ($1,060-$1,350/month) or switch to compounded tirzepatide ($179-$279/month) └─ Yes → Submit prior authorization ├─ PA denied → Appeal, pay cash, or switch to compounded tirzepatide └─ PA approved → Check your copay/coinsurance ├─ Copay ≤$600/month → Use Lilly savings card, pay $25-$50/month ├─ Copay >$600/month → Use Lilly savings card, pay $50-$250/month, or switch to compounded └─ Haven't met deductible → Pay negotiated rate minus savings card ($350-$550/month) until deductible met, then reassess